Samantha Morais obtained a B.Sc. Hons in Science and Technology Studies (2010) from York University in Canada, and a M.Sc. in Epidemiology (2013) and a Ph.D. in Public Health (2018) from the University of Porto in Portugal. For her doctoral thesis (SFRH/BD/102585/2014), she examined the sociodemographic and clinical factors that contribute to the risk of gastric related second primary cancers and estimated the impact of these cancers on the long-term survival of patients. During her postdoctoral training at the Institute of Public Health of the University of Porto, Samantha contributed to the design and implementation of cohort studies (POCI-01-0145-FEDER-032358, ref. PTDC/SAU-EPI/32358/2017), and was a member of the project examining the impact of the COVID-19 pandemic on patients with cancer in Porto, Portugal (Research 4 COVID 174_596850546). She has been an Invited Assistant Professor for Introduction to Epidemiology and Fundamentals of Statistics at the Faculty of Medicine of the University of Porto, and she has (co-)supervised undergraduate and graduate-level students. Her research interests are in cancer epidemiology and public health, with a special focus on the burden of cancer outcomes other than death.
Samantha is currently a Postdoctoral Researcher in the Gerald Bronfman Department of Oncology at McGill University. She joined the Division of Cancer Epidemiology at McGill in September 2021, and she assists the Division’s research program on human papillomavirus infection and associated cancers.
Samantha is a collaborator of the Cancer Epidemiology Lab at the Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional.
Br J Cancer, 2022 May 24. doi: 10.1038/s41416-022-01856-w. Online ahead of print.
Cancer Causes Control, 2022 Mar 19. doi: 10.1007/s10552-022-01565-y. Online ahead of print.
Cancers (Basel), 2022 Mar 7;14(5):1355. doi: 10.3390/cancers14051355.
ESMO Open, 2022 Mar 7;7(2):100448. doi: 10.1016/j.esmoop.2022.100448. Online ahead of print.
Br J Cancer, 2022 Feb 24. doi: 10.1038/s41416-022-01750-5. Online ahead of print.
Cancer Epidemiol Biomarkers Prev, 2022 Jan;31(1):200-209. doi: 10.1158/1055-9965.EPI-21-0402. Epub 2021 Nov 2.
Support Care Cancer, 2021 Nov 24. doi: 10.1007/s00520-021-06702-y. Online ahead of print.
Cancer Epidemiol Biomarkers Prev, 2021 Apr 13;cebp.1730.2020
Breast, 2021 Feb 22;57:1-4. doi: 10.1016/j.breast.2021.02.010. Online ahead of print.
BMJ Open, 2021 Feb 15;11(2):e043844. doi: 10.1136/bmjopen-2020-043844.
Eur J Cancer Prev, 2021 Sep 17. doi: 10.1097/CEJ.0000000000000680. Online ahead of print.
Eur J Cancer Prev, 2021 Aug 26. doi: 10.1097/CEJ.0000000000000720. Online ahead of print.
Cancers (Basel), 2021 Jul 30;13(15):3844. doi: 10.3390/cancers13153844.
Eur J Cancer Prev, 2021 Jul 8. doi: 10.1097/CEJ.0000000000000686. Online ahead of print.
Breast, 2021 May 15;58:130-137. doi: 10.1016/j.breast.2021.05.006. Online ahead of print.
Porto Biomedical Journal, 2021 Apr 13;6(2):e130. doi: 10.1097/j.pbj.0000000000000130. eCollection Mar-Apr 2021.
Int J Cancer, 2021 Feb 26. doi: 10.1002/ijc.33532. Online ahead of print.
ESMO Open, 2020 Nov;5(6):e000984. doi: 10.1136/esmoopen-2020-000984.
Cancers (Basel), 2020 Oct 20;12(10):E3064. doi: 10.3390/cancers12103064.